Literature DB >> 25384508

Genetic polymorphisms in the one-carbon metabolism pathway genes and susceptibility to non-Hodgkin lymphoma.

Sujatha Suthandiram1, Gin-Gin Gan, Shamsul Mohd Zain, Ping-Chong Bee, Lay-Hoong Lian, Kian-Meng Chang, Tee-Chuan Ong, Zahurin Mohamed.   

Abstract

Corroborating evidence related to the role of aberrations on one-carbon metabolism (OCM) genes has been inconsistent. We evaluated the association between polymorphisms in 12 single nucleotide polymorphisms (SNPs) in 8 OCM genes (CBS, FPGS, FTHFD, MTRR, SHMT1, SLC19A1, TCN1, and TYMS), and non-Hodgkin lymphoma (NHL) risk in a multi-ethnic population which includes Malay, Chinese and Indian ethnic subgroups. Cases (N = 372) and controls (N = 722) were genotyped using the Sequenom MassARRAY platform. Our results of the pooled subjects showed a significantly enhanced NHL risk for CBS Ex9 + 33C > T (T versus C: OR 1.55, 95% CI 1.22-1.96, P = 0.0003), CBS Ex18-319G > A (A versus G: OR 1.15, 95% CI 1.14-1.83; P = 0.002), SHMT1 Ex12 + 236 T > C (T versus C: OR 1.44, 95% CI 1.15-1.81, P = 0.002), and TYMS Ex8 + 157C > T (T versus C: OR 1.29, 95% CI 1.06-1.57, P = 0.01). Haplotype analysis for CBS SNPs showed a significantly decreased risk of NHL in subjects with haplotype CG (OR 0.69, 95% CI 0.56-0.86, P = <0.001). The GG haplotype for the FTHFD SNPs showed a significant increased risk of NHL (OR 1.40, 95% CI 1.12-1.76, P = 0.002). For the TYMS gene, haplotype CAT at TYMS (OR 0.67, 95% CI 0.49-0.90, P = 0.007) was associated with decreased risk of NHL, while haplotype TAC (OR 1.29, 95% CI 1.05-1.58, P = 0.01) was found to confer increased risk of NHL. Our study suggests that variation in several OCM genes (CBS, FTHFD, SHMT1, TCN1, and TYMS) may influence susceptibility to NHL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384508     DOI: 10.1007/s13277-014-2785-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

Review 1.  Haplotype analysis in population genetics and association studies.

Authors:  Hongyu Zhao; Ruth Pfeiffer; Mitchell H Gail
Journal:  Pharmacogenomics       Date:  2003-03       Impact factor: 2.533

2.  Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.

Authors:  Unhee Lim; Sophia S Wang; Patricia Hartge; Wendy Cozen; Linda E Kelemen; Stephen Chanock; Scott Davis; Aaron Blair; Maryjean Schenk; Nathaniel Rothman; Qing Lan
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Dietary factors of one-carbon metabolism in relation to non-Hodgkin lymphoma and multiple myeloma in a cohort of male smokers.

Authors:  Unhee Lim; Stephanie Weinstein; Demetrius Albanes; Pirjo Pietinen; Lasse Teerenhovi; Philip R Taylor; Jarmo Virtamo; Rachael Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

4.  Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.

Authors:  Tracy J Lightfoot; Christine F Skibola; Eleanor V Willett; Danica R Skibola; James M Allan; Fabio Coppede; Peter J Adamson; Gareth J Morgan; Eve Roman; Martyn T Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-12       Impact factor: 4.254

5.  Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage.

Authors:  B C Blount; M M Mack; C M Wehr; J T MacGregor; R A Hiatt; G Wang; S N Wickramasinghe; R B Everson; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency.

Authors:  J K Christman; G Sheikhnejad; M Dizik; S Abileah; E Wainfan
Journal:  Carcinogenesis       Date:  1993-04       Impact factor: 4.944

7.  Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway.

Authors:  Aditi Hazra; Peter Kraft; Ross Lazarus; Constance Chen; Stephen J Chanock; Paul Jacques; Jacob Selhub; David J Hunter
Journal:  Hum Mol Genet       Date:  2009-09-10       Impact factor: 6.150

8.  10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells.

Authors:  Sergey A Krupenko; Natalia V Oleinik
Journal:  Cell Growth Differ       Date:  2002-05

9.  Polymorphisms in methylenetetrahydrofolate reductase gene and risk of non-Hodgkin lymphoma in a multi-ethnic population.

Authors:  Sujatha Suthandiram; Gin Gin Gan; Shamsul Mohd Zain; Batoul Sadat Haerian; Ping Chong Bee; Lay Hoong Lian; Kian Meng Chang; Tee Chuan Ong; Zahurin Mohamed
Journal:  J Hum Genet       Date:  2014-03-20       Impact factor: 3.172

10.  Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update.

Authors:  Bryan A Bassig; Qing Lan; Nathaniel Rothman; Yawei Zhang; Tongzhang Zheng
Journal:  J Cancer Epidemiol       Date:  2012-09-12
View more
  4 in total

1.  Gene polymorphisms in the folate metabolic pathway and risk of pediatric acute lymphoblastic leukemia: a case-control study in a Chinese population.

Authors:  Hui Lv; Shao-Yan Hu; Zhi-Zuo Du; Zong Zhai; Lan Cao; Yi-Na Sun; Jun Lu; Jie Li; Hai-Long He; Yi-Huan Chai; Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

2.  Association of MTRR A66G polymorphism with cancer susceptibility: Evidence from 85 studies.

Authors:  Ping Wang; Sanqiang Li; Meilin Wang; Jing He; Shoumin Xi
Journal:  J Cancer       Date:  2017-01-15       Impact factor: 4.207

Review 3.  The Role of Single-Nucleotide Polymorphisms in the Function of Candidate Tumor Suppressor ALDH1L1.

Authors:  Sergey A Krupenko; David A Horita
Journal:  Front Genet       Date:  2019-10-30       Impact factor: 4.599

4.  The association between RFC1 G80A polymorphism and cancer susceptibility: Evidence from 33 studies.

Authors:  Xiaoyi Huang; Yisha Gao; Jing He; Jiao Cai; Na Ta; Hui Jiang; Jinhong Zhu; Jianming Zheng
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.